Insulin resistant states and insulin signaling

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 9, 2003, Pages 1107-1119

  Vollenweider, Peter ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Impaired glucose tolerance; Insulin; Insulin resistance; Insulin signaling; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ENZYME ACTIVATOR; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MEMBRANE PROTEIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR;

ANIMAL MODEL; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; EPIDEMIC; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CYTOSKELETAL PROTEINS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; POLYCYSTIC OVARY SYNDROME; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0142029565     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.173     Document Type: Review

References (109)

1. Frattali AL, Treadway JL, Pessin JE. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation. J Biol Chem 1992; 267:19521-8.
2. Kasuga M, Fujita-Yamaguchi Y, Blithe DL, Kahn CR. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA 1983; 80:2137-41.
3. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182:3-11.
4. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 1994; 269:3568-73.
5. Sharma PM, Egawa K, Huang Y, Martin JL, Huvar I, Boss GR, Olefsky JM. Inhibition of phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on insulin action. J Biol Chem 1998; 273:18528-37.
6. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996; 271:31372-8.
7. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, Quon MJ. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 1997; 11:1881-90.
8. Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, Farese RV. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem 1997; 272:30075-82.
9. Bandyopadhyay G, Kanoh Y, Sajan MP, Standaert ML, Farese RV. Effects of adenoviral gene transfer of wild-type, constitutively active, and kinase-defective protein kinase C-lambda on insulin-stimulated glucose transport in L6 myotubes. Endocrinology 2000; 141:4120-7.
10. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, Hino Y, et al. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol 1998; 18:6971-82.
11. Nave BT, Haigh RJ, Hayward AC, Siddle K, Shepherd PR. Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. Biochem J 1996; 318:55-60.
12. Guilherme A, Czech MP. Stimulation of IRS-1-associated phosphatidylinositol 3-kinase and Akt/protein kinase B but not glucose transport by beta1-integrin signaling in rat adipocytes. J Biol Chem 1998; 273:33119-22.
13. Jiang T, Sweeney G, Rudolf MT, Klip A, Traynor-Kaplan A, Tsien RY. Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:11017-24.
14. Haruta T, Morris AJ, Vollenweider P, Nelson JG, Rose DW, Mueckler M, et al. Ligand-independent GLUT4 translocation induced by guanosine 5′-O-(3-thiotriphosphate) involves tyrosine phosphorylation. Endocrinology 1998; 139:358-64.
15. Ribon V, Saltiel AR. Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. Biochem J 1997; 324:839-45.
16. Ribon V, Printen JA, Hoffman NG, Kay BK, Saltiel AR. A novel, multifuntional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes. Mol Cell Biol 1998; 18:872-9.
17. Mastick CC, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 1997; 272:20706-14.
18. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 2000; 407:202-7.
19. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC,Watson RT, Neudauer CL, et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 2001; 410:944-8.
20. Chiang SH, Hou JC, Hwang J, Pessin JE, Saltiel AR. Cloning and functional characterization of related TC10 isoforms, a subfamily of Rho proteins involved in insulin-stimulated glucose transport. J Biol Chem 2002; 277:13067-73.
21. Watson RT, Shigematsu S, Chiang SH, Mora S, Kanzaki M, Macara IG, et al. Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. J Cell Biol 2001; 154:829-40.
22. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996; 12: 106-9.
23. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, Johnson RS, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372:186-90.
24. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372:182-6.
25. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900-4.
26. Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 1999; 21:230-5.
27. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, et al. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 2002; 109:141-9.
28. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001; 292: 1728-31.
29. Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 1997; 3:1096-101.
30. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995; 377:151-5.
31. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997; 88:561-72.
32. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, Accili D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105:199-205.
33. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 2000; 105:1791-7.
34. Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001; 108:153-60.
35. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3:25-38.
36. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409:729-33.
37. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993; 268:22243-6.
38. Tozzo E, Gnudi L, Kahn BB. Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic over-expression of GLUT4 driven by an adipose-specific promoter. Endocrinology 1997; 138:1604-11.
39. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87-97.
40. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96:329-39.
41. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-5.
42. Chen H, Wertheimer SJ, Lin CH, Katz SL, Amrein KE, Burn P, et al. Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J Biol Chem 1997; 272: 8026-31.
43. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283:1544-8.
44. Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 1997; 100:449-58.
45. Worm D, Vinten J, Staehr P, Henriksen JE, Handberg A, Beck-Nielsen H. Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects. Diabetologia 1996; 39:1208-14.
46. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. J Biol Chem 1997; 272:448-57.
47. Zhang WR, Li PM, Oswald MA, Goldstein BJ. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol 1996;10:575-84.
48. Ren JM, Li PM, Zhang WR, Sweet LJ, Cline G, Shulman GI, et al. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose home-ostasis. Diabetes 1998; 47:493-7.
49. Arrandale JM, Gore-Willse A, Rocks S, Ren JM, Zhu J, Davis A, et al. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 1996; 271:21353-8.
50. Maegawa H, Hasegawa M, Sugai S, Obata T, Ugi S, Morino K, et al. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. J Biol Chem 1999; 274:30236-43.
51. Bollag GE, Roth RA, Beaudoin J, Mochly-Rosen D, Koshland DE Jr. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein-tyrosine kinase activity. Proc Natl Acad Sci USA 1986; 83: 5822-4.
52. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988; 263:3440-7.
53. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-15.
54. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271:665-8.
55. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103:253-9.
56. Vollenweider P, Clodi M, Martin SS, Imamura T, Kavanaugh WM, Olefsky JM. An SH2 domain-containing 5′ inositolphosphatase inhibits insulin- induced GLUT4 translocation and growth factor-induced actin filament rearrangement. Mol Cell Biol 1999; 19:1081-91.
57. Ishihara H, Sasaoka T, Ishiki M, Wada T, Hori H, Kagawa S, et al. Membrane localization of Src homology 2-containing inositol 5′-phosphatase 2 via Shc association is required for the negative regulation of insulin signaling in rat1 fibroblasts overexpressing insulin receptors. Mol Endocrinol 2002; 16:2371-81.
58. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001; 409:92-7.
59. Hori H, Sasaoka T, Ishihara H, Wada T, Murakami S, Ishiki M, et al. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 2002; 51:2387-94.
60. Marion E, Kaisaki PJ, Pouillon V, Gueydan C, Levy JC, Bodson A, et al. The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 2002; 51:2012-7.
61. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995; 373:448-51.
62. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P, Baron AD. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 1998; 101:2377-86.
63. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 1992; 41:465-75.
64. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341:240-6.
65. Kennedy JW, Hirshman MF, Gervino EV, Ocel JV, Forse RA, Hoenig SJ, et al. Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes 1999; 48:1192-7.
66. Andreasson K, Galuska D, Thorne A, Sonnenfeld T, Wallberg-Henriksson H. Decreased insulin-stimulated 3-0-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. Acta Physiol Scand 1991; 142:255-60.
67. Maegawa H, Shigeta Y, Egawa K, Kobayashi M. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes 1991; 40:815-9.
68. Nolan JJ, Freidenberg G, Henry R, Reichart D, Olefsky JM. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocrinol Metab 1994; 78:471-7.
69. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG Jr, et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 2000; 49:284-92.
70. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyper-insulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 1995; 44:1310-7.
71. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation, Diabetes 1997; 46:524-7.
72. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 1999; 104:733-41.
73. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin- dependent diabetes mellitus. Lancet 1993; 342:828-32.
74. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81:1657-9.
75. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb SS. Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest 1994; 94:1141-6.
76. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, et al. The Gly - >Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000; 85:2004-13.
77. Beeson M, Standaert ML, Sajan MP, Kanoh Y, Bandyopadhyay G, Farese RV. Insulin-induced activation of PKC-z is defective in skeletal muscles of type 2 diabetic humans. Amelioration by rosiglitazone [abstract]. Diabetes 2002; 51:A297.
78. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes 1995; 44:936-46.
79. Gaster M, Petersen I, Hojlund K, Poulsen P, Beck-Nielsen H. The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity. Diabetes 2002; 51:921-7.
80. Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998; 47:1555-61.
81. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS)-1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1997; 94:4171-5.
82. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 1991; 87:1072-81.
83. Rondinone CM, Carvalho E, Wesslau C, Smith UP. Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with type II diabetes mellitus. Diabetologia 1999; 42:819-25.
84. Handberg A, Vaag A, Vinten J, Beck-Nielsen H. Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36:668-74.
85. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, et al. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes 2001; 50:2572-8.
86. Storgaard H, Song XM, Jensen CB, Madsbad S, Bjornholm M, Vaag A, et al. Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected]. Diabetes 2001; 50:2770-8.
87. Jackson S, Bagstaff SM, Lynn S, Yeaman SJ, Turnbull DM, Walker M. Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families. Diabetes 2000; 49:1169-77.
88. Krutzfeldt J, Kausch C, Volk A, Klein HH, Rett K, Haring HU, et al. Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. Diabetes 2000; 49:992-8.
89. Vollenweider P, Menard B, Nicod P. Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-3′ kinase activation, and impaired atypical protein kinase C (zeta/lambda) activation in myotubes from obese patients with impaired glucose tolerance. Diabetes 2002; 51:1052-9.
90. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078-82.
91. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165-74.
92. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165-9.
93. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41:1257-66.
94. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993; 264:E197-E202.
95. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96:801-10.
96. Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002; 87:4088-93.
97. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281:E392-E399.
98. Corbould A, Lee A, Wu X, Dunaif A. Skeletal muscle insulin resistance in polycystic ovary syndrome resolves in culture [abstract]. Diabetes 2001; 50:A334.
99. Naz RK, Thurston D, Santoro N. Circulating tumor necrosis factor (TNF)-alpha in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Am J Reprod Immunol 1995; 34:170-5.
100. Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest 1989; 83:23-9.
101. Poretsky L, Seto-Young D, Shrestha A, Dhillon S, Mirjany M, Liu HC, et al. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 2001; 86:3115-9.
102. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876-80.
103. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-306.
104. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976; 294:739-45.
105. Rosenberg AM, Haworth JC, Degroot GW, Trevenen CL, Rechler MM. A case of leprechaunism with severe hyperinsulinemia. Am J Dis Child 1980; 134:170-5.
106. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, et al. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 1998; 83:2830-5.
107. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51:443-8.
108. Malamas MS, Sredy J, Gunawan I, Mihan B, Sawicki DR, Seestaller L, et al. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem 2000; 43:995-1010.
109. Qureshi SA, Ding V, Li Z, Szalkowski D, Biazzo-Ashnault DE, Xie D, et al. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators. J Biol Chem 2000; 275:36590-5.